Intravenous immunoglobulin treatment of the post-polio syndrome: Sustained effects on quality of life variables and cytokine expression after one year follow up

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Gonzalez, Henrik ^a   Khademi, Mohsen ^b   Borg, Kristian ^a   Olsson, Tomas ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cerebrospinal fluid (CSF); Inflammatory cytokines; Intravenous immunoglobulin (IVIG); Post polio syndrome (PPS)

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 23; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BLOOD CELL; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LUMBAR PUNCTURE; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NEUROLOGIC DISEASE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PAIN; PATIENT ASSESSMENT; PHYSICAL PERFORMANCE; POSTPOLIOMYELITIS SYNDROME; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SHORT FORM 36; VISUAL ANALOG SCALE; WALKING; WALKING DISTANCE TEST;

EID: 84863521507     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-167     Document Type: Article

References (32)

1. Farbu E, Gilhus NE, Barnes MP, Borg K, de VM, Driessen A, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur J Neurol 2006, 13:795-801. 10.1111/j.1468-1331.2006.01385.x, 16879288.
2. Gonzalez H, Olsson T, Borg K. Management of postpolio syndrome. Lancet Neurol 2010, 9:634-642. 10.1016/S1474-4422(10)70095-8, 20494327.
3. Trojan DA, Cashman NR. Post-poliomyelitis syndrome. Muscle Nerve 2005, 31:6-19. 10.1002/mus.20259, 15599928.
4. Grimby G, Stalberg E, Sandberg A, Sunnerhagen KS. An 8-year longitudinal study of muscle strength, muscle fiber size, and dynamic electromyogram in individuals with late polio. Muscle Nerve 1998, 21:1428-1437. 10.1002/(SICI)1097-4598(199811)21:11<1428::AID-MUS10>3.0.CO;2-X, 9771666.
5. McComas AJ, Quartly C, Griggs RC. Early and late losses of motor units after poliomyelitis. Brain 1997, 120(Pt 8):1415-1421.
6. Bartholdi D, Gonzalez H, Borg K, Melki J. Absence of SMN gene deletion in post-polio syndrome. Neuromuscul Disord 2000, 10:99. 10.1016/S0960-8966(99)00076-0, 10714583.
7. Cashman NR, Trojan DA. Correlation of electrophysiology with pathology, pathogenesis, and anticholinesterase therapy in post-polio syndrome. Ann N Y Acad Sci 1995, 753:138-150. 10.1111/j.1749-6632.1995.tb27540.x, 7611623.
8. Dalakas MC. Pro-inflammatory cytokines and motor neuron dysfunction: is there a connection in post-polio syndrome?. J Neurol Sci 2002, 205:5-8. 10.1016/S0022-510X(02)00314-3, 12409176.
9. Rekand T, Langeland N, Aarli JA, Vedeler CA. Fcgamma receptor IIIA polymorphism as a risk factor for acute poliomyelitis. J Infect Dis 2002, 186:1840-1843. 10.1086/345769, 12447772.
10. Sharief MK, Hentges R, Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. N Engl J Med 1991, 325:749-755. 10.1056/NEJM199109123251101, 1651456.
11. Fordyce CB, Gagne D, Jalili F, Alatab S, Arnold DL, Da CD, et al. Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci 2008, 271:80-86. 10.1016/j.jns.2008.03.015, 18474371.
12. Gonzalez H, Khademi M, Andersson M, Wallstrom E, Borg K, Olsson T. Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 2002, 205:9-13. 10.1016/S0022-510X(02)00316-7, 12409177.
13. Gonzalez H, Khademi M, Andersson M, Piehl F, Wallstrom E, Borg K, et al. Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 2004, 150:139-144. 10.1016/j.jneuroim.2004.01.010, 15081258.
14. Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus NE, Aarli JA. Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol 2007, 14:60-65. 10.1111/j.1468-1331.2006.01552.x, 17222115.
15. Gonzalez H, Ottervald J, Nilsson KC, Sjogren N, Miliotis T, Von BH, et al. Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation. J Proteomics 2009, 71:670-681. 10.1016/j.jprot.2008.11.014, 19100873.
16. Kaponides G, Gonzalez H, Olsson T, Borg K. Effect of intravenous immunoglobulin in patients with post-polio syndrome - an uncontrolled pilot study. J Rehabil Med 2006, 38:138-140. 10.1080/16501970500441625, 16546773.
17. Gonzalez H, Sunnerhagen KS, Sjoberg I, Kaponides G, Olsson T, Borg K. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 2006, 5:493-500. 10.1016/S1474-4422(06)70447-1, 16713921.
18. Werhagen L, Borg K. Pain in post polio syndrome - effects of intravenous immunglobulin treatment. J Rehabil Med 2011, in press.
19. March of Dimes March of Dimes International Conference on Post Polio Syndrome. Identifying Best Practices in Diagnosis and Care 2000, , White Plains, March of Dimes.
20. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247-263. 10.1097/00005650-199303000-00006, 8450681.
21. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
22. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005, 11:909-918.
23. Elliott TE, Renier CM, Palcher JA. Chronic pain, depression, and quality of life: correlations and predictive value of the SF-36. Pain Med 2003, 4:331-339. 10.1111/j.1526-4637.2003.03040.x, 14750909.
24. Kosinski M, Keller SD, Ware JE, Hatoum HT, Kong SX. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Med Care 1999, 37:MS23-MS39. 10.1097/00005650-199905001-00003, 10335741.
25. Saba J, Quinet RJ, Davis WE, Krousel-Wood M, Chambers R, Gomez N, et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine 2003, 70:348-351. 10.1016/S1297-319X(03)00065-4, 14563462.
26. Ware JE, Kosinski M, Gandek B, Aaronson NK, Apolone G, Bech P, et al. The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International quality of life assessment. J Clin Epidemiol 1998, 51:1159-1165. 10.1016/S0895-4356(98)00107-3, 9817133.
27. Harada ND, Chiu V, Stewart AL. Mobility-related function in older adults: assessment with a 6-minute walk test. Arch Phys Med Rehabil 1999, 80:837-841. 10.1016/S0003-9993(99)90236-8, 10414771.
28. Steffen TM, Hacker TA, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: six-minute walk test, berg balance scale, timed up & go test, and gait speeds. Phys Ther 2002, 82:128-137.
29. Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain 1994, 56:217-226. 10.1016/0304-3959(94)90097-3, 8008411.
30. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011, 17:335-343. 10.1177/1352458510389102, 21135023.
31. Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, et al. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004, 172:7169-7176.
32. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240. 10.1084/jem.20041257, 2212798, 15657292.